Prognostic value of pretreatment systemic immune-inflammation index in patients with endometrial cancer: a meta-analysis.
Biomark Med
; 18(7): 345-356, 2024.
Article
em En
| MEDLINE
| ID: mdl-38623927
ABSTRACT
Background:
The present work focused on evaluating the systemic immune-inflammation index (SII) for its role in predicting endometrial cancer (EC) patient prognosis by meta-analysis.Methods:
SII's role in predicting the prognosis of EC patients was analyzed by calculating combined hazard ratios (HRs) and 95% CIs.Results:
As revealed by combined analysis, an increased SII predicted poor overall survival (HR = 2.01; 95% CI = 1.58-2.57; p < 0.001) as well as inferior progression-free survival (HR = 1.87; 95% CI = 1.36-2.58; p < 0.001) of EC.Conclusion:
An increased SII score significantly predicted poor overall survival and progression-free survival in subjects with EC. The SII is suitable for predicting short- and long-term prognoses of patients with EC.
[Box see text].
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias do Endométrio
/
Inflamação
Limite:
Female
/
Humans
Idioma:
En
Revista:
Biomark Med
Assunto da revista:
BIOQUIMICA
/
MEDICINA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China